Economic Evaluation

Our Unit has extensive experience and expertise in conducting economic evaluations alongside clinical trials, registries and cohort studies.

Economic evaluation generates evidence-based information, through cost-effectiveness analysis, cost-utility analysis or cost-benefit analysis, to assist decision making in allocating health care resources. Evaluating whether health technologies or services provide value for money is critical to ensuring that healthcare resources are allocated in a way that maximises population health.

Our Unit has world-class expertise in the following areas:

  • Diabetes
  • Cardiovascular diseases
  • Arthritis and other musculoskeletal conditions
  • Genomics and precision medicine
  • Child and maternal health
  • Cancer
  • Infectious diseases and infections
  • Mental health and social care

In addition, we also conduct research to improve economic evaluations methods.

The Health Economics Unit provides support to clinical trialists and research groups in grant development and study design. Requests for consultations can be submitted via the Methods and Implementation Support for Clinical and Health Research Hub (MISCH). The Unit also offers a range of training courses in economic evaluation from introductory to advanced levels.

Selected Projects

Improving cost-effectiveness analysis of childhood vaccines
The GP-OSMOTIC T2D trial: GP monitor to improve outcomes in Type 2 Diabetes

The HIPSTER trial

The HUNTER trial

Home-base=d care for febrile neutropenia in children

Health economics studies alongside the Fontan registry

The VITALITY trial

The TEDI prem trial

The PEBBLES trial

The PPOIT trial

The CHOICE trial


RISE trial

IRMA trial

BRISC trial

RAD trial




ASAP Trial

Working Out Dads Trial

Strengthening Care for Children Project

Selected Publications

Goranitis I, Wu Y, Lunke S, White SM, Tan TY, Yeung A, Hunter MF, Martyn M, Gaff C, Stark Z. Is faster better? An economic evaluation of rapid and ultra-rapid genomic testing in critically ill infants and children. Genet Med. 2022 May;24(5):1037-1044. doi: 10.1016/j.gim.2022.01.013.

Tran‐Duy A, Morrisroe K, Clarke P, Stevens W, Proudman S, Sahhar J, Nikpour M, Australian Scleroderma Interest Group (ASIG). Cost‐Effectiveness of Combination Therapy for Patients With Systemic Sclerosis–Related Pulmonary Arterial Hypertension. Journal of the American Heart Association 2021;10(7):e015816.

Huang L, …, Dalziel K. Cost-Effectiveness of Nasal CPAP versus High Flow for Newborn Infants in Special-Care Nurseries. Pediatrics. 2021.

Wu Y, Balasubramaniam S, Rius R, Thorburn DR, Christodoulou J, Goranitis I. Genomic sequencing for the diagnosis of childhood mitochondrial disorders: a health economic evaluation. Eur J Hum Genet. 2021 Jun 8. doi: 10.1038/s41431-021-00916-8. Epub ahead of print. PMID: 34099885.

Dale K, Abayawardana M, McBryde E, Trauer J, Carvalho N. Latent tuberculosis screening and treatment strategies in recent migrants to a low-incidence setting: A cost effectiveness modelling study. Am J of Epi 2021 (In press)

Carvalho N, Hoque ME, Oliver VL, Byrne A, Kermode M, Lambert P, McIntosh MP, Morgan A. Cost-effectiveness of inhaled oxytocin for prevention of postpartum haemorrhage: A modelling study applied to two high burden settings. BMC Medicine 2020; 18(201).

Okeke Ogwulu, C. B., Goranitis, I., Devall, A. J., Cheed, V., Gallos, I. D., Middleton, L. J., ... & Roberts, T. E. The cost‐effectiveness of progesterone in preventing miscarriages in women with early pregnancy bleeding: an economic evaluation based on the PRISM trial. BJOG: An International Journal of Obstetrics & Gynaecology, 2020; 127(6), 757-767.

Kaufman J, Knight AJ, Bryant PA, Babl FE, Dalziel K. Liquid Gold: the cost-effectiveness of urine sample collection methods for young pre-continent children. Archives of Disease in Childhood, 2020, 105(3):253-59.

Coomarasamy A, Harb HM, Devall AJ, Cheed V, Roberts TE, Goranitis I, Ogwulu CB, Williams HM, Gallos ID, Eapen A, Daniels JP, Ahmed A, Bender-Atik R, Bhatia K, Bottomley C, Brewin J, Choudhary M, Crosfill F, Deb S, Duncan WC, Ewer A, Hinshaw K, Holland T, Izzat F, Johns J, Lumsden MA, Manda P, Norman JE, Nunes N, Overton CE, Kriedt K, Quenby S, Rao S, Ross J, Shahid A, Underwood M, Vaithilingham N, Watkins L, Wykes C, Horne AW, Jurkovic D, Middleton LJ. Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT. Health Technol Assess. 2020 Jun;24(33):1-70. doi: 10.3310/hta24330. PMID: 32609084; PMCID: PMC7355406.

Catchpool M, Dalziel K, Mahardya RTK, Harvey AS. Cost-effectiveness of epileptic surgery compared with medical treatment in children with drug-resistant epilepsy. Epilepsy and Behavior, 2019: 97:253-259.

Catchpool M, Ramchand J, Martyn M, Hare DL, James PA, Trainer AH, Knight J, Goranitis I. A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy. Genet Med. 2019 Dec;21(12):2815-2822. doi: 10.1038/s41436-019-0582-2. Epub 2019 Jun 20. PMID: 31222143; PMCID: PMC6892743.

Dalziel, K., Cheek, J. A., Fanning, L., Borland, M. L., Phillips, N., Kochar, A., ... & Babl, F. E. A cost-effectiveness analysis comparing clinical decision rules PECARN, CATCH, and CHALICE with usual care for the management of pediatric head injuryAnnals of emergency medicine, 2019; 73(5), 429-439.

Goranitis I, Lissauer DM, Coomarasamy A, Wilson A, Daniels J, Middleton L, Bishop J, Hewitt CA, Weeks AD, Mhango C, Mataya R, Ahmed I, Oladapo OT, Zamora J, Roberts TE. Antibiotic prophylaxis in the surgical management of miscarriage in low-income countries: a cost-effectiveness analysis of the AIMS trial. Lancet Glob Health. 2019 Sep;7(9):e1280-e1286. doi: 10.1016/S2214-109X(19)30336-5. PMID: 31402008; PMCID: PMC6695526.

Ibrahim LF, Huang L, Hopper SM, Dalziel K, Babl FE, Bryant PA. Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis. The Lancet Infectious Diseases. 2019 Oct 1;19(10):1101-8.

Tew, M., Clarke, P., Thursky, K., & Dalziel, K. Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer PatientsPharmacoEconomics, 2019; 37(7), 931-941.

Ride J. Setting the Boundaries for Economic Evaluation: Investigating Time Horizon and Family Effects in the Case of Postnatal Depression. Value in Health. 2018;21(5):573-580.

MA Boujaoude, AJ Mirelman, K Dalziel, N Carvalho. Accounting for equity considerations in cost-effectiveness analysis: a systematic review of rotavirus vaccine in low-and middle-income countries. Cost Effectiveness and Resource Allocation. 2018; 16 (1), 18

Tran‐Duy, A., Ghiti Moghadam, M., Oude Voshaar, M. A., Vonkeman, H. E., Boonen, A., Clarke, P., ... & Dutch National POET Collaboration. An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open‐Label TrialArthritis & rheumatology, 2018; 70(10), 1557-1564.